EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy

A He iD, B Koszegi iD, S Uzun iD, A Bilgic iD, B C Bozca iD, B Yang iD, M Daneshpazhooh iD, M Boziou, A Patsatsi iD, R Kakuta iD, H Takahashi iD, D Nery und 8 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20149 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von A He und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Autoimmune Diseases, Glucocorticoids, Muscular Diseases, Skin Diseases, Vesiculobullous. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health, Labor and Welfare of Japan, Australasian Blistering Diseases Foundation, UNSW.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with autoimmune blistering diseases (AIBDs) are often exposed to chronic glucocorticoid (GC) treatment with many side effects. Glucocorticoid‐induced myopathy (GIM) is a well‐established side effect, which particularly affects the proximal muscles. The Glucocorticoid Toxicity Index (GTI) is a validated global assessment tool which quantifies GC toxicity over time.

Objectives

This study marks the first study which analyses GIM in patients with AIBDs. The objectives of this study were to utilize the GTI to investigate the nature and prevalence of GIM in AIBD patients and explore potential risk factors.

Methods

This international cohort study was conducted in blistering disease clinics across Australia, China, Greece, Iran, Japan, the Philippines, Turkey and the United States of America between February 2019 and July 2023. The GTI tool was completed by a medical practitioner at each patient visit. Data related to glucocorticoid toxicity were entered into the Steritas GTI 2.0 to generate an aggregate improvement and cumulative worsening score at each visit.

Results

The study included 139 patients. There were 132 episodes of myopathy, and 47.5% of patients developed muscle weakness at some point during the study period. Cumulative GC dose correlated positively with myopathy risk, while average dose and treatment duration were not significant. Older age, male gender and obesity more than doubled the likelihood of developing GIM.

Conclusions

GIM is a common side effect experienced by AIBD patients on GC treatment. Muscle weakness is less likely to occur if cumulative GC dose is less than 0.75 mg/kg/day. Studies of exercise programs to mitigate myopathy and newer alternative treatments to reduce cumulative GC dose should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesGlucocorticoidsMuscular DiseasesSkin Diseases, VesiculobullousAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesRisk Factors

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Department of Dermatology, St George Hospital, Sydney, New South Wales, Australia.
  • Faculty of Medicine, UNSW, Sydney, Australia.
  • Department of Dermatology and Venereology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
  • Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong Province, China.
  • Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Second Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.

ORCID-Profile: A He, B Koszegi, S Uzun, A Bilgic, B C Bozca, B Yang, M Daneshpazhooh, A Patsatsi, R Kakuta, H Takahashi, M Ramirez-Quizon, D Culton, J Johal, D F Murrell

Förderung

  • Ministry of Health, Labor and Welfare of Japan
  • Australasian Blistering Diseases Foundation
  • UNSW
  • Steritas Inc
  • Wellcome Trust
  • University of New South Wales

Zitieren

APA

He, A., Koszegi, B., Uzun, S., Bilgic, A., Bozca, B. C., Yang, B., Daneshpazhooh, M., Boziou, M., Patsatsi, A., Kakuta, R., Takahashi, H., Nery, D., Mundin, C., Ramirez-Quizon, M., Culton, D., McAlpine, S., Johal, J., Shulruf, B., Stone, J. H., & Murrell, D. F. (2025). Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20149

Vancouver

He A, Koszegi B, Uzun S, Bilgic A, Bozca BC, Yang B, et al. Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20149

BibTeX
@article{He2025,
  author = {He, A and Koszegi, B and Uzun, S and Bilgic, A and Bozca, B C and Yang, B and Daneshpazhooh, M and Boziou, M and Patsatsi, A and Kakuta, R and Takahashi, H and Nery, D and Mundin, C and Ramirez-Quizon, M and Culton, D and McAlpine, S and Johal, J and Shulruf, B and Stone, J H and Murrell, D F},
  title = {Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20149}
}
Kostenlos starten →